NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Boston Medical Center are collaborating on a multi-year research study on biomarkers that indicate sensitivity and resistance to standard-of-care checkpoint inhibitors.
The goal of the study is to identify prognostic and predictive immuno-oncology biomarkers across different cancers. The researchers will explore not only tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.